Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
Nat Commun ; 14(1): 2285, 2023 04 21.
Article in English | MEDLINE | ID: mdl-37085477

ABSTRACT

Normothermic machine perfusion (NMP) has emerged as an innovative organ preservation technique. Developing an understanding for the donor organ immune cell composition and its dynamic changes during NMP is essential. We aimed for a comprehensive characterization of immune cell (sub)populations, cell trafficking and cytokine release during liver NMP. Single-cell transcriptome profiling of human donor livers prior to, during NMP and after transplantation shows an abundance of CXC chemokine receptor 1+/2+ (CXCR1+/CXCR2+) neutrophils, which significantly decreased during NMP. This is paralleled by a large efflux of passenger leukocytes with neutrophil predominance in the perfusate. During NMP, neutrophils shift from a pro-inflammatory state towards an aged/chronically activated/exhausted phenotype, while anti-inflammatory/tolerogenic monocytes/macrophages are increased. We herein describe the dynamics of the immune cell repertoire, phenotypic immune cell shifts and a dominance of neutrophils during liver NMP, which potentially contribute to the inflammatory response. Our findings may serve as resource to initiate future immune-interventional studies.


Subject(s)
Liver Transplantation , Humans , Aged , Liver Transplantation/methods , Liver , Perfusion/methods , Organ Preservation/methods , Sequence Analysis, RNA
2.
Front Immunol ; 13: 982018, 2022.
Article in English | MEDLINE | ID: mdl-36311746

ABSTRACT

The liver has been proposed as an important "immune organ" of the body, as it is critically involved in a variety of specific and unique immune tasks. It contains a huge resident immune cell repertoire, which determines the balance between tolerance and inflammation in the hepatic microenvironment. Liver-resident immune cells, populating the sinusoids and the space of Disse, include professional antigen-presenting cells, myeloid cells, as well as innate and adaptive lymphoid cell populations. Machine perfusion (MP) has emerged as an innovative technology to preserve organs ex vivo while testing for organ quality and function prior to transplantation. As for the liver, hypothermic and normothermic MP techniques have successfully been implemented in clinically routine, especially for the use of marginal donor livers. Although there is evidence that ischemia reperfusion injury-associated inflammation is reduced in machine-perfused livers, little is known whether MP impacts the quantity, activation state and function of the hepatic immune-cell repertoire, and how this affects the inflammatory milieu during MP. At this point, it remains even speculative if liver-resident immune cells primarily exert a pro-inflammatory and hence destructive effect on machine-perfused organs, or in part may be essential to induce liver regeneration and counteract liver damage. This review discusses the role of hepatic immune cell subtypes during inflammatory conditions and ischemia reperfusion injury in the context of liver transplantation. We further highlight the possible impact of MP on the modification of the immune cell repertoire and its potential for future applications and immune modulation of the liver.


Subject(s)
Organ Preservation , Reperfusion Injury , Humans , Organ Preservation/methods , Perfusion/methods , Liver , Inflammation
3.
World J Surg ; 44(12): 4236-4244, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32901324

ABSTRACT

BACKGROUND: Post-operative pancreatic fistula (POPF) remains a critical complication after pancreatic resection. This prospective pilot study evaluates perioperative markers of pancreatitis and systemic inflammation to predict clinically relevant grade B/C-POPF (CR-POPF). METHODS: All patients undergoing pancreatic resection from December 2017 to April 2019 were prospectively enrolled. Surgical procedures and outcomes were correlated with perioperative blood markers. ROC analysis was performed to assess their predictive value for CR-POPF. Cut-offs were calculated with the Youden index. RESULTS: In total, 70 patients were analysed (43 pancreatoduodenectomies and 27 distal pancreatectomies). In-hospital/90-d mortality and morbidity were 5.7/7.1% (n = 4/n = 5) and 75.7% (n = 53). Major complications (Clavien-Dindo ≥ 3a) occurred in 28 (40.0%) patients, CR-POPF in 20 (28.6%) patients. Serum lipase (cut-off > 51U/L) and IL-6 (> 56.5 ng/l) on POD3 were significant predictors for CR-POPF (AUC = 0.799, 95%-CI 0.686-0.912 and AUC = 0.784, 95%-CI 0.668-0.900; combined AUC = 0.858, 95%-CI 0.758-0.958; all p < 0.001). Patients with both or one factor(s) above cut-off more frequently developed CR-POPF than cases without (100 vs. 50% vs. 7.5%, p < 0.001). This also applied for overall and severe complications (p = 0.013 and p = 0.009). CONCLUSIONS: Post-operative pancreatitis and inflammatory response are major determinants for development of POPF. A combination of serum lipase and IL-6 on POD3 is a highly significant early predictor of CR-POPF and overall complications, potentially guiding patient management. CLINICAL TRIAL REGISTRATION: The study protocol was registered at clinicaltrials.gov (NCT04294797).


Subject(s)
Pancreatic Fistula , Pancreatitis , Humans , Interleukin-6 , Lipase , Pancreatic Fistula/diagnosis , Pancreatic Fistula/etiology , Pancreaticoduodenectomy , Pilot Projects , Postoperative Complications , Prospective Studies , Risk Factors , Systemic Inflammatory Response Syndrome/diagnosis , Systemic Inflammatory Response Syndrome/etiology
5.
J Neural Transm (Vienna) ; 124(4): 501-509, 2017 04.
Article in English | MEDLINE | ID: mdl-27909828

ABSTRACT

We showed previously that higher levels in CSF dopamine in HIV patients are associated with the presence of the dopamine transporter (DAT) 10/10-repeat allele which was also detected more frequently in HIV-infected individuals compared to uninfected subjects. In the current study, we investigated further whether other genetic dopamine (DA)-related polymorphisms may be related with changes in CSF DA levels and frequency of HIV infection in HIV-infected subjects. Specifically, we studied genetic polymorphisms of brain-derived neurotrophic factor, catechol-O-methyltransferase, and dopamine receptors DRD2, DRD3, and DRD4 genetic polymorphisms in uninfected and HIV-infected people in two different ethnical groups, a German cohort (Caucasian, 72 individuals with HIV infection and 22 individuals without HIV infection) and a South African cohort (Xhosan, 54 individuals with HIV infection and 19 individuals without HIV infection). We correlated the polymorphisms with CSF DA levels, HIV dementia score, CD4+ T cell counts, and HIV viral load. None of the investigated DA-related polymorphisms was associated with altered CSF DA levels, CD4+ T cell count, viral load, and HIV dementia score. The respective allele frequencies were equally distributed between HIV-infected patients and controls. Our findings do not show any influence of the studied genetic polymorphisms on CSF DA levels and HIV infection. This is in contrast to what we found previously for the DAT 3'UTR VNTR and highlights the specific role of the DAT VNTR in HIV infection and disease.


Subject(s)
Brain-Derived Neurotrophic Factor/genetics , Catechol O-Methyltransferase/genetics , Dopamine/cerebrospinal fluid , HIV Infections/cerebrospinal fluid , HIV Infections/genetics , Receptors, Dopamine/genetics , Adult , Biomarkers/cerebrospinal fluid , CD4 Lymphocyte Count , Cohort Studies , Female , Gene Frequency , Genotyping Techniques , Germany , Humans , Male , Middle Aged , Neuropsychological Tests , Polymorphism, Genetic , Risk , Severity of Illness Index , South Africa , Viral Load
7.
Eur J Neurol ; 20(7): 1032-42, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23419064

ABSTRACT

BACKGROUND AND PURPOSE: Firategrast is an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS). This could decrease multiple sclerosis (MS) activity, but may compromise CNS immune surveillance. We aimed to quantitate the effect of firategrast treatment on cerebrospinal fluid (CSF) lymphocyte count and the extent/speed of recovery after its discontinuation. METHODS: Forty-six subjects with relapsing forms of MS were treated for up to 24 weeks with open-label firategrast, 900 (females) or 1200 (males) mg twice daily. CSF and blood cell counts, and lymphocyte composition were determined using flow cytometry. RESULTS: Median (n, range) CSF lymphocyte counts (cells/µl) at weeks 0, 24, 28 and 36 were: 5.3 (44, 0.3-70.2), 3.3 (31, 0.0-99.0), 3.0 (32, 0.0-58.2) and 3.5 (29, 0.0-274.8). CD4+, CD8+ T- and CD19+ B-lymphocyte counts followed a similar pattern. Minimal changes were observed for CD3-CD16+CD56+ natural killer cells. Median CD4 : CD8 ratios were: 2.9 (41, 1.1-10.9), 2.2 (29, 0.6-5.9), 3.8 (28, 1.6-9.0) and 3.8 (21, 2.1-9.4). Blood lymphocyte counts were elevated at weeks 4 and 24, consistent with the mechanism of firategrast, and returned to baseline when firategrast was discontinued. There were minimal changes in CD4 : CD8 ratios. CONCLUSIONS: Firategrast treatment was associated with modest decreases in median CSF total, CD4, CD8 and CD19 lymphocyte counts. The generally small magnitude of decreases suggests that sufficient numbers of lymphocytes can access the subarachnoid space, preserving CNS immune surveillance.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Integrin alpha4beta1/antagonists & inhibitors , Integrins/antagonists & inhibitors , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/immunology , Adult , Anti-Inflammatory Agents/adverse effects , Female , Humans , Leukocyte Count , Lymphocyte Count , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/cerebrospinal fluid , Treatment Outcome
8.
Neoplasma ; 59(6): 747-55, 2012.
Article in English | MEDLINE | ID: mdl-22862176

ABSTRACT

Because of its semi-solid character in dissemination and growth, advanced ovarian cancer with its hundreds of peritoneal tumor nodules and plaques appears to be an excellent in vivo model for studying the cancer stem cell hypothesis. The most important obstacle, however, is to adequately define and isolate these tumor-initiating cells endowed with the properties of anoikis-resistance and unlimited self-renewal. Until now, no universal single marker or marker constellation has been found to faithfully isolate (ovarian) cancer stem cells. As these multipotent cells are known to possess highly elaborated efflux systems for cytotoxic agents, these pump systems have been exploited to outline putative stem cells as a side-population (SP) via dye exclusion analysis. Furthermore, the cells in question have been isolated via flow cytometry on the basis of cell surface markers thought to be characteristic for stem cells.In the Vienna variant of the ovarian cancer cell line A2780 a proof-of-principle model with both a stable SP and a stable ALDH1A1+ cell population was established. Double staining clearly revealed that both cell fractions were not identical. Of note, A2780V cells were negative for expression of surface markers CD44 and CD117 (c-kit). When cultured on monolayers of healthy human mesothelial cells, green-fluorescence-protein (GFP)-transfected SP of A2780V exhibited spheroid-formation, whereas non-side-population (NSP) developed a spare monolayer growing over the healthy mesothelium. Furthermore, A2780V SP was found to be partially resistant to platinum. However, this resistance could not be explained by over-expression of the "excision repair cross-complementation group 1" (ERCC1) gene, which is essentially involved in the repair of platinated DNA damage. ERCC1 was, nonetheless, over-expressed in A2780V cells grown as spheres under stem cell-selective conditions as compared to adherent monolayers cultured under differentiating conditions. The same was true for the primary ovarian cancer cells B-57.In summary our investigations indicate that even in multi-passaged cancer cell lines hierarchic government of growth and differentiation is conserved and that the key cancer stem cell population may be composed of small overlapping cell fractions defined by various arbitrary markers.


Subject(s)
Neoplastic Stem Cells/physiology , Ovarian Neoplasms/pathology , Animals , Cell Separation , Coculture Techniques , DNA-Binding Proteins/genetics , Drug Resistance, Neoplasm , Drug Screening Assays, Antitumor , Endonucleases/genetics , Female , Humans , Ovarian Neoplasms/drug therapy
9.
J Med Primatol ; 39(4): 243-51, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20618590

ABSTRACT

BACKGROUND: Chronic immune activation is a hallmark of HIV infection and has been postulated as major factor in the pathogenesis of AIDS. Recent evidence suggests that activation of immune cells is triggered by microbial translocation through the impaired gastrointestinal barrier. METHODS: To determine the association between microbial translocation and disease progression, we have retrospectively analyzed microbial products, viral load and markers of immune activation in a cohort of 37 simian immunodeficiency virus-infected rhesus monkeys, divided in two groups with distinct disease courses. RESULTS: As seen in HIV-infected patients, we found elevated levels of lipopolysaccharide (LPS) in infected animals. However, LPS levels or LPS control mechanisms like endotoxin core antibodies or LPS-binding protein did not differ between groups with different disease progression. In contrast, neopterin, a metabolic product of activated macrophages, was higher in fast progressors than in slow progressors. CONCLUSION: Our data indicate that translocation of microbial products is not the major driving force of immune activation in HIV infection.


Subject(s)
Bacterial Translocation , Intestinal Mucosa/microbiology , Simian Acquired Immunodeficiency Syndrome/microbiology , Simian Immunodeficiency Virus , Viral Load , Animals , Cross-Sectional Studies , Intestinal Mucosa/metabolism , Lipopolysaccharides/blood , Macaca mulatta , Retrospective Studies , Simian Acquired Immunodeficiency Syndrome/immunology , beta Carotene/metabolism
10.
J Neural Transm (Vienna) ; 117(6): 699-705, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20454983

ABSTRACT

Central dopaminergic (DA) systems are affected during human immunodeficiency virus (HIV) infection. So far, it is believed that they degenerate with progression of HIV disease because deterioration of DA systems is evident in advanced stages of infection. In this manuscript we found that (a) DA levels are increased and DA turnover is decreased in CSF of therapy-naïve HIV patients in asymptomatic infection, (b) DA increase does not modulate the availability of DA transporters and D2-receptors, (c) DA correlates inversely with CD4+ numbers in blood. These findings show activation of central DA systems without development of adaptive responses at DA synapses in asymptomatic HIV infection. It is probable that DA deterioration in advanced stages of HIV infection may derive from increased DA availability in early infection, resulting in DA neurotoxicity. Our findings provide a clue to the synergism between DA medication or drugs of abuse and HIV infection to exacerbate and accelerate HIV neuropsychiatric disease, a central issue in the neurobiology of HIV.


Subject(s)
Dopamine/metabolism , HIV Infections/metabolism , HIV Infections/pathology , Synaptic Transmission/physiology , 3,4-Dihydroxyphenylacetic Acid/cerebrospinal fluid , Adult , Benzamides , CD4 Antigens/metabolism , Case-Control Studies , Chemokine CCL2/metabolism , Galactosephosphates/metabolism , HIV/genetics , HIV Infections/cerebrospinal fluid , HIV Infections/diagnostic imaging , HIV Infections/immunology , Homovanillic Acid/cerebrospinal fluid , Humans , Male , Middle Aged , Pyrrolidines , Tomography, Emission-Computed, Single-Photon/methods , Tropanes , Viral Load/methods
11.
J Neural Transm Suppl ; (72): 317-22, 2007.
Article in English | MEDLINE | ID: mdl-17982909

ABSTRACT

In this study we investigated differences in the gene expression profiling of the brains of rhesus macaques that were uninfected or infected with SIV in the asymptomatic stage or AIDS. The main aim was to use biostatistical methods to classify brain gene expression following SIV infection, without consideration of the biological significance of the individual genes. We also used data from animals treated with different pharmacological substances such as dopaminergic drugs, N-methyl-D-aspartate (NMDA) antagonists or antioxidants during the early stage of infection as these animals exhibited an accelerated or attenuated neuropsychiatric disease progression. We found macaque subspecies to be a more important factor for disease classification based on gene expression profiling than clinical symptoms or neuropathological findings. It is noteworthy that SIV-infected pharmacologically-treated. Chinese animals clustered near uninfected animals independent on the outcome of the treatment, whereas untreated SIV infected animals were clustered in a separate subtree. It is clear from this study that NeuroAIDS is a diverse disease entity and that SIV brain genes can be differentially regulated, depending on the disease type as well as changed dependent on the monkey subspecies.


Subject(s)
Biometry/methods , Brain/virology , Gene Expression Profiling/statistics & numerical data , Macaca mulatta/genetics , Oligonucleotide Array Sequence Analysis/statistics & numerical data , Simian Acquired Immunodeficiency Syndrome/genetics , Simian Immunodeficiency Virus/genetics , Algorithms , Animals , Bayes Theorem , China , Cluster Analysis , Disease Progression , Encephalitis, Viral/genetics , Encephalitis, Viral/virology , Gene Expression Regulation, Viral/physiology , India , Linear Models , Putamen/virology , Simian Acquired Immunodeficiency Syndrome/virology , Species Specificity , Viremia/genetics , Viremia/virology , Virus Replication/genetics
12.
J Neurovirol ; 10(3): 163-70, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15204921

ABSTRACT

The basal ganglia, structures rich in the neurotransmitter dopamine, are primarily affected during human immunodeficiency virus (HIV) infection. The authors measured levels of dopamine and its metabolites, homovanillic acid and 3,4-dihydroxyphenylacetic acid, in brains of uninfected and simian immunodeficiency virus (SIV)-infected rhesus monkeys during the asymptomatic stage of the infection. Moreover, the authors investigated changes in cyclic adenosine monophosphate (cAMP) and cAMP response element-binding protein (CREB), two factors involved in the signaling pathway of dopamine. The brain regions examined were the nucleus accumbens and the corpus amygdaloideum, which are limbic structures of the basal ganglia that are involved in the pathophysiology of psychiatric disorders and substance abuse. Dopamine content was reduced in both regions of SIV-infected monkeys compared to uninfected animals. Moreover, dopamine deficits were associated with a decrease in expression of total CREB. Intracellular concentrations of cAMP were decreased in nucleus accumbens and remained unchanged in corpus amygdaloideum of SIV-infected macaques. Changes in dopamine signaling were not related to pathology or viral load of the investigated animals. The results suggest that dopamine defects precede neurologic deficits and implicate dysfunction of the dopaminergic system in the etiopathogenesis of HIV dementia. Therefore, affective complications in HIV subjects should not be interpreted only as reactive psychological changes. The alterations in the mesolimbic dopaminergic system during asymptomatic stage of SIV infection implicate a biological background for psychiatric disorders in HIV infection.


Subject(s)
Brain/metabolism , Cyclic AMP/metabolism , Dopamine/metabolism , Signal Transduction/physiology , Simian Acquired Immunodeficiency Syndrome/physiopathology , 3,4-Dihydroxyphenylacetic Acid/analysis , 3,4-Dihydroxyphenylacetic Acid/metabolism , Animals , Brain/pathology , Brain/virology , Chromatography, High Pressure Liquid , Cyclic AMP Response Element-Binding Protein/metabolism , Dopamine/analysis , Electrophoresis, Polyacrylamide Gel , Homovanillic Acid/analysis , Homovanillic Acid/metabolism , Immunoblotting , Immunohistochemistry , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Immunodeficiency Virus/physiology
13.
Acta Neuropathol ; 107(3): 216-26, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14712399

ABSTRACT

Drug abuse and human immunodeficiency virus (HIV) infection seem to cause cumulative damage in the central nervous system (CNS). Elevated extracellular dopamine is thought to be a prime mediator of the reinforcing effects of addictive substances. To investigate the possible role of increased dopamine availability in the pathogenesis of HIV dementia, simian immunodeficiency virus (SIV)-infected monkeys were treated with dopaminergic drugs (selegiline or L-DOPA). Both substances increased intracerebral SIV expression, combined with aggravation of infection-related neuropathology and ultrastructural alterations of dendrites in dopaminergic areas (spongiform polioencephalopathy) in asymptomatic animals. Moreover, this treatment resulted in enhanced TNF-alpha expression in the brains of SIV-infected animals. These findings indicate a synergistic interaction between dopamine and SIV infection on microglia activation, leading to increased viral replication and production of neurotoxic substances. Our results suggest that increased dopamine availability through dopaminergic medication or addictive substances may potentiate HIV dementia.


Subject(s)
Dopamine Agents/adverse effects , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/drug effects , Animals , Cell Count/methods , Central Nervous System Viral Diseases/pathology , Central Nervous System Viral Diseases/virology , Dose-Response Relationship, Drug , Gene Expression/drug effects , Immunohistochemistry/methods , In Situ Hybridization/methods , Inflammation/etiology , Inflammation/pathology , Inflammation/virology , Interleukin-1/metabolism , Interleukin-6/metabolism , Levodopa/adverse effects , Macaca mulatta , Monoamine Oxidase/metabolism , Selegiline/adverse effects , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Immunodeficiency Virus/physiology , Staining and Labeling/methods , Statistics, Nonparametric , Time Factors , Tumor Necrosis Factor-alpha/metabolism , Virus Replication/drug effects
14.
J Neurovirol ; 8 Suppl 2: 129-33, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12491164

ABSTRACT

Human immunodeficiency virus (HIV) infection is associated with psychiatric complications, including cognitive impairment, affective disorders, and psychosis. These psychiatric complications impair quality of life, affect disease prognosis, and impede treatment by compromising medication adherence. They also increase the likelihood of HIV transmission, either directly or via their high prevalence rate among drug abusers. In this article, the authors provide a brief overview of the most common psychiatric complications associated with HIV infection and discuss the role of dopamine as a link between psychiatric manifestations and the progression of immunodeficiency infection.


Subject(s)
AIDS Dementia Complex/psychology , Mood Disorders/virology , Psychotic Disorders/virology , AIDS Dementia Complex/complications , Humans
15.
J Neural Transm (Vienna) ; 109(5-6): 747-66, 2002 May.
Article in English | MEDLINE | ID: mdl-12111465

ABSTRACT

The pathogenesis of HIV-induced neurological disorders is still incompletely understood. Since many aspects of this disease are difficult to explore in humans, animal models are necessary to fill the gaps in our knowledge. Based on the high concordance with the human system, the SIV-infection of macaques currently provides the best animal model to study pathogenesis, therapy and prevention of HIV-infection. In this review, important features of the CNS-infection in this model are outlined. Recent virological, immunological, neurophysiological and neurochemical findings obtained with this animal model are presented and key factors in the development of neurological disease are identified.


Subject(s)
AIDS Dementia Complex , Brain Diseases/virology , Disease Models, Animal , Macaca , Primate Diseases/pathology , Primate Diseases/physiopathology , Simian Acquired Immunodeficiency Syndrome/complications , AIDS Dementia Complex/pathology , AIDS Dementia Complex/physiopathology , AIDS Dementia Complex/virology , Animals , Brain Diseases/pathology , Brain Diseases/physiopathology , Humans
16.
J Neural Transm (Vienna) ; 109(5-6): 767-75, 2002 May.
Article in English | MEDLINE | ID: mdl-12111466

ABSTRACT

A great number of human immunodeficiency virus (HIV)-infected patients develop a central nervous system disorder, commonly called HIV dementia or AIDS dementia complex (ADC). HIV dementia is independent of opportunistic infections and is due to the virus itself. Symptoms include psychomotor slowing, apathy and motor disorders similar to the bradykinesia and postural and gait abnormalities observed in late Parkinson's disease. Consequently, HIV has been discussed during the last few years as an additional cause for parkinsonism, and parkinsonian syndromes as manifestations of HIV dementia. Moreover, the early phase of HIV infection gains increasing interest because of studies which report subtle neurological symptoms at this stage. Accordingly, we found in SIV-infected monkeys that dopamine is reduced by 44% within as few as two months of infection, indicating that changes during early infection must be thoroughly evaluated. In this short review, we discuss alterations in the nigrostriatal dopaminergic system during early and late immunodeficiency virus infection and the common clinical and biochemical features shared by HIV dementia and Parkinson's disease.


Subject(s)
AIDS Dementia Complex/complications , Parkinsonian Disorders/virology , Corpus Striatum/metabolism , Dopamine Agents/therapeutic use , Humans , Parkinsonian Disorders/drug therapy , Parkinsonian Disorders/physiopathology , Substantia Nigra/metabolism
18.
J Neural Transm (Vienna) ; 109(3): 399-410, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11956960

ABSTRACT

HIV compromises immunological functions. Immune responses are regulated to a great extent by several molecules such as cytokines, neurotransmitters and hormones which interact with different immune effector cells and ultimately mediate the homeostatic responses to disease. Among these mediators, dopamine plays an important role. In this article we review AIDS Dementia Complex (ADC) and describe lines of evidence implying increased dopamine availability as a potent mediator of neurologic deficits in HIV infection and a factor exhibiting adverse effects on the progression of ADC.


Subject(s)
AIDS Dementia Complex/metabolism , Brain/metabolism , Brain/virology , Dopamine/metabolism , Neurons/metabolism , Neurons/virology , AIDS Dementia Complex/drug therapy , AIDS Dementia Complex/physiopathology , Animals , Antiparkinson Agents/adverse effects , Brain/physiopathology , Disease Progression , Humans
19.
Acta Neuropathol ; 101(2): 85-91, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11271377

ABSTRACT

Human immunodeficiency virus infection (HIV) at late stages of the disease is accompanied by neurological complications, including motor, behavioral and cognitive impairment. Using simian immunodeficiency virus (SIV)-infected rhesus monkeys, an animal model of HIV infection, we found that during the asymptomatic SIV infection dopamine (DA) deficits are early components of central nervous system (CNS) dysfunction. To investigate the role of the DA system in SIV infection and to restore the DA deficiency, we administered selegiline, an agent with DAergic and neuroprotective properties, to SIV-infected monkeys. Selegiline increased DA availability but induced CNS vacuolization, SIV encephalitic lesions, and enhanced CNS viral replication during early SIV infection. The pathological changes seem to be mediated by DA, as treatment with L-DOPA, the precursor of DA, had similar effects. We propose that any natural or induced DAergic dysregulation which results in increased DA availability may potentiate HIV-associated neurological disease (ND). Our findings raise new questions regarding the pathogenesis of HIV-ND and generate concerns about the safety of dopaminergic drugs in the clinical management of HIV-infected patients.


Subject(s)
AIDS Dementia Complex/drug therapy , Central Nervous System/drug effects , Dopamine Agonists/adverse effects , Dopamine/metabolism , Simian Acquired Immunodeficiency Syndrome/drug therapy , Simian Immunodeficiency Virus/drug effects , AIDS Dementia Complex/pathology , AIDS Dementia Complex/physiopathology , Animals , Central Nervous System/pathology , Central Nervous System/physiopathology , Dendrites/drug effects , Dendrites/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Encephalitis, Viral/drug therapy , Encephalitis, Viral/pathology , Encephalitis, Viral/physiopathology , Macaca mulatta , Neuroprotective Agents/adverse effects , Selegiline/adverse effects , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Acquired Immunodeficiency Syndrome/physiopathology , Simian Immunodeficiency Virus/physiology , Time Factors , Vacuoles/drug effects , Vacuoles/pathology , Virus Replication/drug effects , Virus Replication/physiology
20.
Eur J Pharmacol ; 411(1-2): R1-R2, 2001 Jan 05.
Article in English | MEDLINE | ID: mdl-11137877

ABSTRACT

Human immunodeficiency virus (HIV) infection is associated with a progressive dementia, in addition to motor and behavioural deficits. Cognitive deterioration and motor impairments have been observed also in simian immunodeficiency virus (SIV)-infected monkeys, an animal model for HIV infection. We found recently that choline acetyltransferase activity is markedly reduced in brains of SIV-infected monkeys. We report now that selegiline, completely restores the reduced choline acetyltransferase activity which encourages for a meaningful anti-dementia therapeutic strategy.


Subject(s)
Choline O-Acetyltransferase/drug effects , Monoamine Oxidase Inhibitors/pharmacology , Selegiline/pharmacology , Simian Acquired Immunodeficiency Syndrome/enzymology , Simian Immunodeficiency Virus , Animals , Brain/drug effects , Brain/enzymology , Choline O-Acetyltransferase/metabolism , Dose-Response Relationship, Drug , Hippocampus/drug effects , Hippocampus/enzymology , Macaca mulatta , Putamen/drug effects , Putamen/enzymology , Simian Acquired Immunodeficiency Syndrome/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...